{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T20:10:37Z","timestamp":1769026237147,"version":"3.49.0"},"reference-count":25,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2022,4,13]],"date-time":"2022-04-13T00:00:00Z","timestamp":1649808000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["K08 AI151253-01"],"award-info":[{"award-number":["K08 AI151253-01"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Antibiotics"],"abstract":"<jats:p>Outpatient treatment of Pseudomonas aeruginosa infections is challenged by increasing rates of resistance to fluoroquinolones, the only class of antibiotics which offers an established oral route of administration against this organism. Azithromycin does not demonstrate activity against P. aeruginosa when evaluated under standard methods of susceptibility testing with bacteriologic media. However, growing evidence shows that azithromycin is very active against P. aeruginosa when using physiologic media that recapitulate the in vivo milieu and is supported by animal models of infection and various clinical settings, including cystic fibrosis. We present three cases of outpatient management of P. aeruginosa otolaryngological infections successfully treated with oral azithromycin, 500 mg daily ranging from 3\u20138 weeks, where use of fluoroquinolones was not possible due to either resistance or patient intolerance. We review the previous data supporting this clinical approach, in the hope that this will alert clinicians to this treatment option and to inspire a more thorough clinical trial evaluation of azithromycin in this environment of growing medical need.<\/jats:p>","DOI":"10.3390\/antibiotics11040515","type":"journal-article","created":{"date-parts":[[2022,4,13]],"date-time":"2022-04-13T00:42:34Z","timestamp":1649810554000},"page":"515","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Azithromycin: An Underappreciated Quinolone-Sparing Oral Treatment for Pseudomonas aeruginosa Infections"],"prefix":"10.3390","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0330-278X","authenticated-orcid":false,"given":"Erlinda R.","family":"Ulloa","sequence":"first","affiliation":[{"name":"Department of Pediatrics, School of Medicine, University of California Irvine, Irvine, CA 92697, USA"},{"name":"Division of Infectious Disease, Children\u2019s Hospital of Orange County, Orange, CA 92868, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"George","family":"Sakoulas","sequence":"additional","affiliation":[{"name":"Sharp Rees-Stealy Medical Group, San Diego, CA 92123, USA"},{"name":"Collaborative to Halt Antibiotic-Resistant Microbes (CHARM), Department of Pediatrics, School of Medicine, University of California San Diego, La Jolla, CA 92093, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2022,4,13]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1016\/j.ebiom.2015.05.021","article-title":"Azithromycin Synergizes with Cationic Antimicrobial Peptides to Exert Bactericidal and Therapeutic Activity Against Highly Multidrug-Resistant Gram-Negative Bacterial Pathogens","volume":"2","author":"Lin","year":"2015","journal-title":"EBioMedicine"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1093\/jac\/dkv487","article-title":"Standard susceptibility testing overlooks potent azithromycin activity and cationic peptide synergy against MDR Stenotrophomonas maltophilia","volume":"71","author":"Kumaraswamy","year":"2016","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1097\/IM9.0000000000000014","article-title":"Azithromycin Exerts Bactericidal Activity and Enhances Innate Immune Mediated Killing of MDR Achromobacter xylosoxidans","volume":"2","author":"Ulloa","year":"2020","journal-title":"Infect. Microbes Dis."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"3883","DOI":"10.1128\/AAC.00457-13","article-title":"Azithromycin Attenuates Lung Inflammation in a Mouse Model of Ventilator-Associated Pneumonia by Multidrug-Resistant Acinetobacter baumannii","volume":"57","author":"Yamada","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1007\/s00228-011-1161-x","article-title":"Macrolides: From in vitro anti-inflammatory and immunomodulatory properties to clinical practice in respiratory diseases","volume":"68","author":"Zarogoulidis","year":"2012","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1164\/rccm.201207-1160OE","article-title":"Cystic fibrosis pulmonary guidelines. Chronic medications for maintenance of lung health","volume":"187","author":"Mogayzel","year":"2013","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_7","unstructured":"U.S. Food & Drug Administration (2022, March 19). Fluoroquinolone Antimicrobial Drugs Information, Available online: https:\/\/www.fda.gov\/drugs\/information-drug-class\/fluoroquinolone-antimicrobial-drugs-information."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1002\/jor.21196","article-title":"Ciprofloxacin up-regulates tendon cells to express matrix metalloproteinase-2 with degradation of type I collagen","volume":"29","author":"Tsai","year":"2011","journal-title":"J. Orthop. Res."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"S27","DOI":"10.1086\/511159","article-title":"Infectious Diseases Society of America\/American Thoracic Society Consensus Guidelines on the Management of Community-Acquired Pneumonia in Adults","volume":"44","author":"Mandell","year":"2007","journal-title":"Clin. Infect. Dis."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.ijantimicag.2009.10.009","article-title":"Synergistic effects of dexamethasone and quinolones on human-derived tendon cells","volume":"35","author":"Sendzik","year":"2010","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2353","DOI":"10.1093\/cid\/ciab452","article-title":"Current Paradigms of Combination Therapy in Methicillin-Resistant Staphy-lococcus aureus (MRSA) Bacteremia: Does it Work, Which Combination, and For Which Patients?","volume":"73","author":"Rose","year":"2021","journal-title":"Clin. Infect. Dis."},{"key":"ref_12","unstructured":"Centers for Disease Control and Prevention (2022, March 19). Risk for COVID-19 Infection, Hospitalization, and Death by Age Group, Available online: https:\/\/www.cdc.gov\/coronavirus\/2019-ncov\/covid-data\/investigations-discovery\/hospitalization-death-by-age.html."},{"key":"ref_13","first-page":"155","article-title":"Azithromycin, cardiovascular risks, QTc interval prolongation, torsade de pointes, and regulatory issues: A narrative review based on the study of case reports","volume":"1","author":"Hancox","year":"2013","journal-title":"Ther. Adv. Infect. Dis."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"20338","DOI":"10.1073\/pnas.1307797110","article-title":"Genome-scale metabolic reconstructions of multiple Escherichia coli strains highlight strain-specific adaptations to nutritional environments","volume":"110","author":"Monk","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Gajd\u00e1cs, M., Bar\u00e1th, Z., K\u00e1rp\u00e1ti, K., Szab\u00f3, D., Usai, D., Zanetti, S., and Donadu, M.G. (2021). No Correlation between Biofilm Formation, Virulence Factors, and Antibiotic Resistance in Pseudomonas aeruginosa: Results from a Laboratory-Based In Vitro Study. Antibiotics, 10.","DOI":"10.3390\/antibiotics10091134"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2414","DOI":"10.1128\/JCM.06686-11","article-title":"Cation Concentration Variability of Four Distinct Mueller-Hinton Agar Brands Influences Polymyxin B Susceptibility Results","volume":"50","author":"Girardello","year":"2012","journal-title":"J. Clin. Microbiol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1021\/acsinfecdis.7b00194","article-title":"Bicarbonate Alters Bacterial Susceptibility to Antibiotics by Targeting the Proton Motive Force","volume":"4","author":"Farha","year":"2018","journal-title":"ACS Infect. Dis."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"5842","DOI":"10.1128\/JCM.42.12.5842-5845.2004","article-title":"Azithromycin Retards Pseudomonas aeruginosa Biofilm Formation","volume":"42","author":"Gillis","year":"2004","journal-title":"J. Clin. Microbiol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1093\/jac\/31.5.681","article-title":"Inhibition of Pseudomonas aeruginosa virulence factors by subinhibitory con-centrations of azithromycin and other macrolide antibiotics","volume":"31","author":"Molinari","year":"1993","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1007\/BF01961867","article-title":"Inhibition of motility of Pseudomonas aeruginosa and Proteus mirabilis by subinhibitory con-centrations of azithromycin","volume":"11","author":"Molinari","year":"1992","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"3677","DOI":"10.1128\/AAC.01011-06","article-title":"Azithromycin Blocks Quorum Sensing and Alginate Polymer Formation and Increases the Sensitivity to Serum and Stationary-Growth-Phase Killing of Pseudomonas aeruginosa and Attenuates Chronic P. aeruginosa Lung Infection in Cftr\u2212\/\u2212 Mice","volume":"51","author":"Hoffmann","year":"2007","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s15010-001-0031-3","article-title":"Buccal adherence of Pseudomonas aeruginosa in patients with cystic fibrosis under long-term therapy with azithromycin","volume":"29","author":"Baumann","year":"2001","journal-title":"Infection"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1159\/000238989","article-title":"Interference by Subinhibitory Concentrations of Azithromycin with the Mechanism of Bacterial Adhesion to Human Epithelial Cells","volume":"39","author":"Braga","year":"1993","journal-title":"Chemotherapy"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"33519","DOI":"10.1073\/pnas.2007626117","article-title":"Identification of novel targets of azithromycin activity against Pseudomonas aeruginosa grown in physiologically relevant media","volume":"117","author":"Belanger","year":"2020","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1093\/cid\/cis473","article-title":"Increased Susceptibility of Pseudomonas aeruginosa to Macrolides and Ketolides in Eukaryotic Cell Culture Media and Biological Fluids Due to Decreased Expression of oprM and Increased Outer-Membrane Permeability","volume":"55","author":"Buyck","year":"2012","journal-title":"Clin. Infect. Dis."}],"container-title":["Antibiotics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2079-6382\/11\/4\/515\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T22:52:54Z","timestamp":1760136774000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2079-6382\/11\/4\/515"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,13]]},"references-count":25,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2022,4]]}},"alternative-id":["antibiotics11040515"],"URL":"https:\/\/doi.org\/10.3390\/antibiotics11040515","relation":{},"ISSN":["2079-6382"],"issn-type":[{"value":"2079-6382","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,13]]}}}